Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited

Cytokine and Growth Factor Reviews

Volumn 20, Issue 4, 2009, Pages 271-281

  Decker, William K ^a   Safdar, Amar ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AIDS; Cancer; Growth factors; Hepatitis; Interferon; Interleukin; Leukemia; Lymphoma; Tuberculosis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BETA INTERFERON; CD40 LIGAND; CD40 LIGAND AGONIST; CD40 LIGAND AGONIST ANTIBODY; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INFLIXIMAB; INTERLEUKIN 2; LAMIVUDINE; LONG ACTING DRUG; MELPHALAN; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT SOLUBLE CD40 LIGAND; RIBAVIRIN; RITUXIMAB; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENTIATION; EPIDEMIC ENCEPHALITIS; ERADICATION THERAPY; FEBRILE NEUTROPENIA; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION; INFECTION PREVENTION; LIVER TOXICITY; LOW DRUG DOSE; MELANOMA; MENINGOENCEPHALITIS; MULTIPLE ORGAN FAILURE; MYCOSIS; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; RHEUMATIC DISEASE; SOFT TISSUE SARCOMA; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; YELLOW FEVER;

BACILLI (CLASS); BACTERIA (MICROORGANISMS); MAMMALIA; STREPTOCOCCUS;

EID: 69249218860     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2009.07.004     Document Type: Note

References (187)

1. Burdick C.G. William Bradley Coley 1862-1936. Ann Surg 105 January (1) (1937) 152-155
2. Hoption Cann S.A., van Netten J.P., and van N.C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79 December (938) (2003) 672-680
3. Levine D.B. The hospital for the ruptured and crippled: William Bradley Coley, Third Surgeon-in-Chief 1925-1933. HSS J 4 February (1) (2008) 1-9
4. McCarthy E.F. The toxins of William B, Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 26 (2006) 154-158
5. Starnes C.O. Coley's toxins in perspective. Nature 357 May (6373) (1992) 11-12
6. Gay N.J., and Keith F.J. Drosophila Toll and IL-1 receptor. Nature 351 May (6325) (1991) 355-356
7. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., and Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86 September (6) (1996) 973-983
8. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 July (6640) (1997) 394-397
9. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 December (5396) (1998) 2085-2088
10. Colonna M., Trinchieri G., and Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 5 December (12) (2004) 1219-1226
11. Decker W.K., Xing D., and Shpall E.J. Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transpl 12 February (2) (2006) 113-125
12. Guiducci C., Ott G., Chan J.H., et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 203 August (8) (2006) 1999-2008
13. McKenna K., Beignon A.S., and Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 79 January (1) (2005) 17-27
14. Piccioli D., Sammicheli C., Tavarini S., et al. Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood 113 April (18) (2009) 4232-4239
15. Schmidt J., Patrut E.M., Ma J., et al. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother 55 November (11) (2006) 1396-1405
16. Barnes E., Salio M., Cerundolo V., et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother 48 September (9) (2004) 3382-3389
17. Schmidt J., Jager D., Hoffmann K., Buchler M.W., and Marten A. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother 30 January (1) (2007) 108-115
18. van Koetsveld P.M., Vitale G., de Herder W.W., et al. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab 91 November (11) (2006) 4537-4543
19. Jia S.F., An T., Worth L., and Kleinerman E.S. Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide. J Interferon Cytokine Res 19 June (6) (1999) 617-624
20. Manara M.C., Serra M., Benini S., Picci P., and Scotlandi K. Effectiveness of Type I interferons in the treatment of multidrug resistant osteosarcoma cells. Int J Oncol 24 February (2) (2004) 365-372
21. Belardelli F., Ferrantini M., Proietti E., and Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13 April (2) (2002) 119-134
22. Davis I.D., Jefford M., Parente P., and Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol 73 January (1) (2003) 3-29
23. Pfeffer L.M., Dinarello C.A., Herberman R.B., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58 June (12) (1998) 2489-2499
24. Petropoulos D., Worth L.L., Mullen C.A., Lockhart S., Choroszy M., and Chan K.W. Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma. Bone Marrow Transpl 38 September (5) (2006) 345-349
25. Garbe C., and Eigentler T.K. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17 April (2) (2007) 117-127
26. Riker A.I., Radfar S., Liu S., Wang Y., and Khong H.T. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 7 March (3) (2007) 345-358
27. Kubo S., Nishiguchi S., Hirohashi K., et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134 May (10) (2001) 963-967
28. Lo C.M., Liu C.L., Chan S.C., et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245 June (6) (2007) 831-842
29. Strander H. Interferons and osteosarcoma. Cytokine Growth Factor Rev 18 October (5-6) (2007) 373-380
30. Perabo F.G., and Muller S.C. Current and new strategies in immunotherapy for superficial bladder cancer. Urology 64 September (3) (2004) 409-421
31. Poordad F., Reddy K.R., and Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 46 January (1) (2008) 78-84
32. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 April (4) (2004) 1147-1171
33. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 September (13) (2002) 975-982
34. Ferenci P., Fried M.W., Shiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 September (3) (2005) 425-433
35. Huang Y., Staschke K., De F.R., and Tan S.L. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication?. Virology 364 July (1) (2007) 1-9
36. Hui C.K., Leung N., Shek T.W., et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 46 September (3) (2007) 690-698
37. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 June (26) (2005) 2682-2695
38. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 September (12) (2004) 1206-1217
39. Vithanomsat S., Wasi C., Harinasuta C., and Thongcharoen P. The effect of interferon on flaviviruses in vitro: a preliminary study. Southeast Asian J Trop Med Public Health 15 March (1) (1984) 27-31
40. Saxena S.K., Mathur A., and Srivastava R.C. Inhibition of Japanese encephalitis virus infection by diethyldithiocarbamate is independent of its antioxidant potential. Antivir Chem Chemother 14 March (2) (2003) 91-98
41. Solomon T., Dung N.M., Wills B., et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 361 March (9360) (2003) 821-826
42. Stephen E.L., Sammons M.L., Pannier W.L., Baron S., Spertzel R.O., and Levy H.B. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis 136 July (1) (1977) 122-126
43. Rahal J.J., Anderson J., Rosenberg C., Reagan T., and Thompson L.L. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis 190 September (6) (2004) 1084-1087
44. Lewis M., and Amsden J.R. Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. Pharmacotherapy 27 March (3) (2007) 455-458
45. Sayao A.L., Suchowersky O., Al-Khathaami A., et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci 31 May (2) (2004) 194-203
46. Samuel M.A., and Diamond M.S. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 79 November (21) (2005) 13350-13361
47. Herberman R.B. Summary: potential of interleukin-2 for the therapy of cancer. J Biol Response Mod 3 October (5) (1984) 527-532
48. Lissoni P., Barni S., Rovelli F., and Tancini G. Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report. Oncology 48 2 (1991) 125-127
49. Grande C., Firvida J.L., Navas V., and Casal J. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 17 January (1) (2006) 1-12
50. Nicolini A., Carpi A., and Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 17 October (5) (2006) 325-337
51. Hess V., Herrmann R., Veelken H., and Schwabe M. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting. Oncology 73 1-2 (2007) 33-40
52. Ives N.J., Stowe R.L., Lorigan P., and Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol 25 December (34) (2007) 5426-5434
53. McDermott D.F. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 13 January (2 Pt 2) (2007) 716s-720s
54. Negrier S., Maral J., Drevon M., Vinke J., Escudier B., and Philip T. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 6 February (Suppl 1) (2000) S93-S98
55. Petrella T., Quirt I., Verma S., Haynes A.E., Charette M., and Bak K. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 33 August (5) (2007) 484-496
56. Dieli F., Vermijlen D., Fulfaro F., et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67 August (15) (2007) 7450-7457
57. Jin P., Wang E., Provenzano M., Stroncek D., and Marincola F.M. Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. Crit Rev Immunol 27 5 (2007) 437-448
58. Cangiano T., Liao J., Naitoh J., Dorey F., Figlin R., and Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 17 February (2) (1999) 523-528
59. Motzer R.J., Bacik J., Mariani T., Russo P., Mazumdar M., and Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 May (9) (2002) 2376-2381
60. Upton M.P., Parker R.A., Youmans A., McDermott D.F., and Atkins M.B. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28 September (5) (2005) 488-495
61. Keilholz U., Conradt C., Legha S.S., et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 16 September (9) (1998) 2921-2929
62. Phan G.Q., Attia P., Steinberg S.M., White D.E., and Rosenberg S.A. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19 August (15) (2001) 3477-3482
63. Zorn E., Nelson E.A., Mohseni M., et al. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108 September (5) (2006) 1571-1579
64. Hryniewicz A., Boasso A., Edghill-Smith Y., et al. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 108 December (12) (2006) 3834-3842
65. Porter B.O., Anthony K.B., Shen J., et al. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. AIDS 23 January (2) (2009) 203-212
66. Mier J.W., Vachino G., Klempner M.S., et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76 November (10) (1990) 1933-1940
67. Kovacs J.A., Lempicki R.A., Sidorov I.A., et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 115 August (8) (2005) 2139-2148
68. Emery S., Capra W.B., Cooper D.A., et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis 182 August (2) (2000) 428-434
69. Sereti I., Martinez-Wilson H., Metcalf J.A., et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood 100 September (6) (2002) 2159-2167
70. Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev 13 April (2) (2002) 135-141
71. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72 September (9) (1975) 3666-3670
72. Lejeune F.J., Lienard D., Matter M., and Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6 (2006) 6
73. Lin Y., Devin A., Rodriguez Y., and Liu Z.G. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 13 October (19) (1999) 2514-2526
74. Lienard D., Ewalenko P., Delmotte J.J., Renard N., and Lejeune F.J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10 January (1) (1992) 52-60
75. Nakamoto T., Inagawa H., Takagi K., and Soma G. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res 20 November (6A) (2000) 4087-4096
76. Rossi C.R., Foletto M., Pilati P., Mocellin S., and Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol 29 August (4) (2002) 400-409
77. Rothbarth J., Tollenaar R.A., and van d.V. Recent trends and future perspectives in isolated hepatic perfusion in the treatment of liver tumors. Expert Rev Anticancer Ther 6 April (4) (2006) 553-565
78. Foa R., Massaia M., Cardona S., et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 76 July (2) (1990) 393-400
79. Herrmann F., Helfrich S.G., Lindemann A., Schleiermacher E., Huber C., and Mertelsmann R. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia. J Clin Oncol 10 April (4) (1992) 631-634
80. Vinante F., Rigo A., Tecchio C., et al. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome. Br J Haematol 102 September (4) (1998) 1025-1034
81. Warzocha K., Salles G., Bienvenu J., et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 15 February (2) (1997) 499-508
82. Hsu H., Shu H.B., Pan M.G., and Goeddel D.V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84 January (2) (1996) 299-308
83. Song H.Y., Regnier C.H., Kirschning C.J., Goeddel D.V., and Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 94 September (18) (1997) 9792-9796
84. Warzocha K., Ribeiro P., Bienvenu J., et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91 May (10) (1998) 3574-3581
85. Davies F.E., Rollinson S.J., Rawstron A.C., et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 18 August (15) (2000) 2843-2851
86. Oh B.R., Sasaki M., Perinchery G., et al. Frequent genotype changes at 308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol 163 May (5) (2000) 1584-1587
87. Hajeer A.H., Lear J.T., Ollier W.E., et al. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas. Br J Dermatol 142 March (3) (2000) 441-445
88. Ghaderi M., Nikitina L., Peacock C.S., et al. Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev 9 October (10) (2000) 1067-1070
89. Bartlett D.L., Libutti S.K., Figg W.D., Fraker D.L., and Alexander H.R. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129 February (2) (2001) 176-187
90. Rothbarth J., Pijl M.E., Vahrmeijer A.L., et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 90 November (11) (2003) 1391-1397
91. De Vries M.R., Borel R.I., van d V., et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 147 (1998) 107-119
92. Glazier D.B., Bahnson R.R., McLeod D.G., von Roemeling R.W., Messing E.M., and Ernstoff M.S. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J Urol 154 July (1) (1995) 66-68
93. Serretta V., Piazza B., Pavone C., Piazza S., and Pavone-Macaluso M. Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors?-a phase II study. Int J Urol 2 May (2) (1995) 100-103
94. Sternberg C.N., Arena M.G., Pansadoro V., et al. Recombinant tumor necrosis factor for superficial bladder tumors. Ann Oncol 3 November (9) (1992) 741-745
95. Brassard P., Kezouh A., and Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43 September (6) (2006) 717-722
96. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8 October (10) (2008) 601-611
97. Kuderer N.M., Dale D.C., Crawford J., and Lyman G.H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25 July (21) (2007) 3158-3167
98. Lopez-Lazaro M. Granulocyte colony-stimulating factor (G-CSF): a novel anticancer therapy based on the "universal dynamics of tumor growth"?. Exp Oncol 28 September (3) (2006) 249-251
99. Dissemond J., Weimann T.K., Schneider L.A., et al. Activated neutrophils exert antitumor activity against human melanoma cells: reactive oxygen species-induced mechanisms and their modulation by granulocyte-macrophage-colony-stimulating factor. J Invest Dermatol 121 October (4) (2003) 936-938
100. Zivkovic M., Poljak-Blazi M., Egger G., Sunjic S.B., Schaur R.J., and Zarkovic N. Oxidative burst and anticancer activities of rat neutrophils. Biofactors 24 1-4 (2005) 305-312
101. Koga Y., Matsuzaki A., Suminoe A., Hattori H., and Hara T. Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res 64 February (3) (2004) 1037-1043
102. Bosch X. Physicists describe new way to study tumours. Lancet 353 January (9146) (1999) 44
103. Bru A., Pastor J.M., Fernaud I., Bru I., Melle S., and Berenguer C. Super-rough dynamics on tumor growth. Phys Rev Lett 81 November (18) (1998) 4008-4011
104. Bru A., Albertos S., Subiza J.L., Garcia-Asenjo J.L., and Bru I. The universal dynamics of tumor growth. Biophys J 85 November (5) (2003) 2948-2961
105. Bru A., Albertos S., Garcia-Asenjo J.L., and Bru I. Pinning of tumoral growth by enhancement of the immune response. Phys Rev Lett 92 June (23) (2004)
106. Burton A. Fractal tumour contours question therapy strategies. Lancet Oncol 2 May (5) (2001) 253
107. Bru A., Albertos S., Garcia-Hoz F., and Bru I. Regulation of neutrophilia by granulocyte colony-stimulating factor: a new cancer therapy that reversed a case of terminal hepatocellular carcinoma. J Clin Res 8 (2005) 9-13 [Ref Type: Generic]
108. Benz R., Goede J.S., Parlier V., Muhlematter D., Jotterand M., and Fehr J. G-CSF-induced remission in two cases of acute myeloid leukemia. Leuk Res 32 July (7) (2008) 1148-1152
109. Piccaluga P.P., Martinelli G., Malagola M., et al. Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature. Haematologica 88 August (8) (2003) ECR28
110. Toki H., Matsutomo S., Okabe K., and Shimokawa T. Remission in hypoplastic acute myeloid leukaemia induced by granulocyte colony-stimulating factor. Lancet 1 June (8651) (1989) 1389-1390
111. Xavier L., Cunha M., Goncalves C., et al. Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy. Leuk Lymphoma 44 December (12) (2003) 2137-2142
112. Britschgi C., Jenal M., Rizzi M., et al. HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation. Br J Haematol 141 April (2) (2008) 179-187
113. Bottoni U., Bonaccorsi P., Devirgiliis V., et al. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. Jpn J Clin Oncol 35 September (9) (2005) 507-513
114. Adler B.K., Salzman D.E., Carabasi M.H., Vaughan W.P., Reddy V.V., and Prchal J.T. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 97 May (10) (2001) 3313-3314
115. Gertz M.A., Lacy M.Q., Bjornsson J., and Litzow M.R. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res 9 October (5) (2000) 635-643
116. O'Malley D.P., Whalen M., and Banks P.M. Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. Am J Hematol 73 August (4) (2003) 294-295
117. Mueller M.M., Herold-Mende C.C., Riede D., Lange M., Steiner H.H., and Fusenig N.E. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol 155 November (5) (1999) 1557-1567
118. Natori T., Sata M., Washida M., Hirata Y., Nagai R., and Makuuchi M. G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 297 October (4) (2002) 1058-1061
119. Segawa K., Ueno Y., and Kataoka T. In vivo tumor growth enhancement by granulocyte colony-stimulating factor. Jpn J Cancer Res 82 April (4) (1991) 440-447
120. Yokoyama T., Hyodo M., Hosoya Y., et al. Aggressive G-CSF-producing gastric cancer complicated by lung and brain abscesses, mimicking metastases. Gastric Cancer 8 3 (2005) 198-201
121. Bodey G.P., Buckley M., Sathe Y.S., and Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64 February (2) (1966) 328-340
122. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 July (19) (2006) 3187-3205
123. Aapro M.S., Cameron D.A., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42 October (15) (2006) 2433-2453
124. Crawford J., Ozer H., Stoller R., et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325 July (3) (1991) 164-170
125. Trillet-Lenoir V., Green J., Manegold C., et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A 3 (1993) 319-324
126. Schroder C.P., de Vries E.G., Mulder N.H., et al. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. J Antimicrob Chemother 43 May (5) (1999) 741-743
127. Hackshaw A., Sweetenham J., and Knight A. Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin's lymphoma?. Br J Cancer 90 April (7) (2004) 1302-1305
128. Bohlius J., Herbst C., Reiser M., Schwarzer G., and Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 4 (2008) CD003189
129. Frankfurt O., and Tallman M.S. Growth factors in leukemia. J Natl Compr Canc Netw 5 February (2) (2007) 203-215
130. Robin G., Markovich S., Athamna A., and Keisari Y. Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures. Lymphokine Cytokine Res 10 August (4) (1991) 257-263
131. Schuster S.J., Venugopal P., Kern J.C., and McLaughlin P. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma 49 September (9) (2008) 1681-1692
132. Steis R.G., VanderMolen L.A., Longo D.L., et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J Natl Cancer Inst 82 April (8) (1990) 697-703
133. Young D.A., Lowe L.D., and Clark S.C. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 145 July (2) (1990) 607-615
134. Gazitt Y., Shaughnessy P., and Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 10 February (1) (2001) 177-186
135. Shaughnessy P.J., Bachier C., Lemaistre C.F., Akay C., Pollock B.H., and Gazitt Y. Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors. Stem Cells 24 July (7) (2006) 1789-1797
136. Charak B.S., Agah R., and Mazumder A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 81 June (12) (1993) 3474-3479
137. Connor R.I., Shen L., and Fanger M.W. Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level. J Immunol 145 September (5) (1990) 1483-1489
138. Keler T., Wallace P.K., Vitale L.A., et al. Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages. J Immunol 164 June (11) (2000) 5746-5752
139. Cochran A.J., Huang R.R., Lee J., Itakura E., Leong S.P., and Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6 September (9) (2006) 659-670
140. Pinedo H.M., Buter J., Luykx-de Bakker S.A., et al. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur J Cancer 39 May (8) (2003) 1061-1067
141. Si Z., Hersey P., and Coates A.S. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 6 June (3) (1996) 247-255
142. Vaquerano J.E., Cadbury P., Treseler P., Sagebiel R., and Leong S.P. Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factor. Arch Dermatol 135 October (10) (1999) 1276-1277
143. Becker P.S. Growth factor priming in therapy of acute myelogenous leukemia. Curr Hematol Rep 3 November (6) (2004) 413-418
144. Bohlius J., Reiser M., Schwarzer G., and Engert A. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 122 August (3) (2003) 413-423
145. Rini B.I., Stadler W.M., Spielberger R.T., Ratain M.J., and Vogelzang N.J. Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma: a phase II trial. Cancer 82 April (7) (1998) 1352-1358
146. Cartron G., Zhao-Yang L., Baudard M., et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 26 June (16) (2008) 2725-2731
147. Olivieri A., Lucesole M., Capelli D., et al. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transpl 11 August (8) (2005) 627-636
148. Rowe J.M., Andersen J.W., Mazza J.J., et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86 July (2) (1995) 457-462
149. Sculier J.P., Paesmans M., Lecomte J., et al. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 85 November (10) (2001) 1444-1451
150. Carr R., Brocklehurst P., Dore C.J., and Modi N. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet 373 January (9659) (2009) 226-233
151. Gil-Lamaignere C., Simitsopoulou M., Roilides E., Maloukou A., Winn R.M., and Walsh T.J. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 191 April (7) (2005) 1180-1187
152. Gil-Lamaignere C., Winn R.M., Simitsopoulou M., Maloukou A., Walsh T.J., and Roilides E. Inteferon gamma and granulocyte-macrophage colony-stimulating factor augment the antifungal activity of human polymorphonuclear leukocytes against Scedosporium spp.: comparison with Aspergillus spp. Med Mycol 43 May (3) (2005) 253-260
153. Roilides E., Blake C., Holmes A., Pizzo P.A., and Walsh T.J. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 34 January (1) (1996) 63-69
154. Bodey G.P., Anaissie E., Gutterman J., and Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis 13 Suppl 2 (1994) S18-S22
155. Safdar A., Rodriguez G., Rolston K.V., et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transpl 39 February (3) (2007) 157-164
156. Safdar A., Rodriguez G.H., Lichtiger B., et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 106 June (12) (2006) 2664-2671
157. Lewis R., Hogan H., Howell A., and Safdar A. Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leuk Lymphoma 49 January (1) (2008) 163-165
158. Loskog A., and Totterman T.H. CD40L-a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 7 March (1) (2007) 23-28
159. Tong A.W., and Stone M.J. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 10 January (1) (2003) 1-13
160. Banchereau J., Paczesny S., Blanco P., et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann NY Acad Sci 987 April (2003) 180-187
161. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 April (4) (2005) 296-306
162. Hartgers F.C., Figdor C.G., and Adema G.J. Towards a molecular understanding of dendritic cell immunobiology. Immunol Today 21 November (11) (2000) 542-545
163. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
164. Behrens G., Li M., Smith C.M., et al. Helper T cells, dendritic cells and CTL immunity. Immunol Cell Biol 82 February (1) (2004) 84-90
165. Bennett S.R., Carbone F.R., Karamalis F., Miller J.F., and Heath W.R. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186 July (1) (1997) 65-70
166. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., and Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393 June (6684) (1998) 478-480
167. Schoenberger S.P., Toes R.E., van d V., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 June (6684) (1998) 480-483
168. van Mierlo G.J., den Boer A.T., Medema J.P., et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 99 April (8) (2002) 5561-5566
169. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., and Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96 November (9) (2000) 2917-2924
170. Eliopoulos A.G., Davies C., Knox P.G., et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 20 August (15) (2000) 5503-5515
171. Gallagher N.J., Eliopoulos A.G., Agathangelo A., Oates J., Crocker J., and Young L.S. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol Pathol 55 April (2) (2002) 110-120
172. Ghamande S., Hylander B.L., Oflazoglu E., Lele S., Fanslow W., and Repasky E.A. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 61 October (20) (2001) 7556-7562
173. Hirano A., Longo D.L., Taub D.D., et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93 May (9) (1999) 2999-3007
174. Posner M.R., Cavacini L.A., Upton M.P., Tillman K.C., Gornstein E.R., and Norris Jr. C.M. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 5 August (8) (1999) 2261-2270
175. Tong A.W., Papayoti M.H., Netto G., et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 7 March (3) (2001) 691-703
176. Wingett D.G., Vestal R.E., Forcier K., Hadjokas N., and Nielson C.P. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 50 July (1) (1998) 27-36
177. Von L.A., van der B.P., Pahl H.L., Aruffo A., and Simon J.C. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59 March (6) (1999) 1287-1294
178. Funakoshi S., Longo D.L., Beckwith M., et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83 May (10) (1994) 2787-2794
179. Hess S., and Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 183 January (1) (1996) 159-167
180. Marches R., Racila E., Tucker T.F., et al. Tumour dormancy and cell signalling-III: role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Ther Immunol 2 June (3) (1995) 125-136
181. Schultze J.L., Cardoso A.A., Freeman G.J., et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92 August (18) (1995) 8200-8204
182. Schultze J.L., Michalak S., Seamon M.J., et al. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Investig 100 December (11) (1997) 2757-2765
183. Johnson P.W., Watt S.M., Betts D.R., et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 82 September (6) (1993) 1848-1857
184. Kluin-Nelemans H.C., Beverstock G.C., Mollevanger P., et al. Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. Blood 84 November (9) (1994) 3134-3141
185. Vonderheide R.H., Dutcher J.P., Anderson J.E., et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19 July (13) (2001) 3280-3287
186. Law C.L., Gordon K.A., Collier J., et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody. SGN-40. Cancer Res 65 September (18) (2005) 8331-8338
187. de Vere Tyndall A., Knight S.C., Edwards A.J., and Clarke J.B. Veiled (dendritic) cells in synovial fluid. Lancet 1 8322 (1983) 472-473